T-cell redirecting bispecific antibodies for treatment of disease
US-9315567-B2 · Apr 19, 2016 · US
Anti-CLL-1 antibodies and immunoconjugates
US11084877B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11084877-B2 |
| Application number | US-201916250398-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 17, 2019 |
| Priority date | Sep 12, 2014 |
| Publication date | Aug 10, 2021 |
| Grant date | Aug 10, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
First claim
Opening claim text (preview).
What is claimed is: 1. An immunoconjugate having the formula Ab-(L-D)p, wherein: (a) Ab is an antibody that binds to CLL-1, wherein the antibody comprises (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:8; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:9, 43, or 44; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:10; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:7; (b) L is a linker; (c) D is a cytotoxic agent and the cytotoxic agent is a drug; and (d) p ranges from 1-8. 2. The immunoconjugate of claim 1 , wherein the antibody comprises HVR-H2 comprising the amino acid sequence of SEQ ID NO:9. 3. The immunoconjugate of claim 1 , wherein the antibody comprises HVR-H2 comprising the amino acid sequence of SEQ ID NO:43. 4. The immunoconjugate of claim 1 , wherein the antibody comprises HVR-H2 comprising the amino acid sequence of SEQ ID NO:44. 5. The immunoconjugate of claim 4 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 33 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32.
Assignees
Inventors
Classifications
of the blood, e.g. leukaemia · CPC title
Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM · CPC title
specific for leukemia · CPC title
containing six-membered rings with nitrogen as a ring hetero atom · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11084877B2 cover?
- The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2851. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).